July 15, 2016
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.
Contact us if you’re interested in a copy of the presentation.
By Rubina Pal, PhD, Flow Cytometry Scientist
By Hillary Reif, Administrative Assistant/Research Associate I and Christine Samuelson, Administrative Assistant
Preclinical oncology studies are a critical step in developing effective cancer therapies. Patient-derived xenograft (PDX) models have become a ...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
© 2025 Translational Drug Development. All Rights Reserved. Terms and Conditions | Privacy Policy
